Dear customers, friends, partners and colleagues：
Since Genova settled in Changzhou high-tech Zone, Jiangsu Province in 2015, it has overcome difficulties, forged ahead, made every effort to build a technical platform and production platform with the world's leading prokaryotic Epro genetic engineering as the core, focused on the development of recombinant protein drugs, combined with imitation and innovation, and adhered to differentiated development. We hope to promote the early entry of more high-quality biological drugs into the market, improve the accessibility of drugs, reduce the drug cost burden of patients and benefit patients all over the world.
After years of efforts, Genova has grown into an innovative multinational pharmaceutical enterprise with global industrial chain layout, bringing together a group of technical experts with international biopharmaceutical experience. It has R & D and production bases in San Diego, California and Hokkaido, Japan. At present, our platform is carrying the transformation task from biotechnology R & D to biopharmaceutical production.
Scan widely in China, the great health industry of medicine has ushered in an era of vigorous development. The market echoes the Internet, and science and technology complement medical treatment. Driven by national policies such as consistency evaluation, centralized purchase with quantity and integration with ICH, the drug market will usher in steady growth and revolutionary innovation. In the critical period of market reform and the fate moment of the alternation of new and old products, Whether we can seize the once-in-a-lifetime opportunity is particularly important.
In front of the tide of the times, Genova will make use of the world-class biopharmaceutical capacity to respond to the national drug centralized purchase policy and provide high-quality and low-cost drugs for patients in low-income countries and regions for a long time. At the same time, Genova will utilize strong process development capacity and sufficient production capacity to undertake the entrusted CDMO business of Covid-19 vaccine, make full use of the mega-scale emergency production capacity potential and contribute to the global fight against the epidemic. We firmly believe that the principle of quality over profit and quality first will lead Genova to a broader world market. We will also make incalculable changes in the future because we stick to our original intention.
Adhering to the core values of "doing the right thing first, doing everything well", Genova will actively enrich product pipelines, continuously optimize and improve technology platforms, and sustain improving product quality. At the same time, Genova will work together with global regional partners through the efforts of all for mutual benefit. Our beautiful vision of "patient first, the quality of each drug is related to the life and health of each patient" will be realized as soon as possible.
The future will belong to everyone who works hard for the pharmaceutical industry!
Dr. Chun Shen
Genova CEO
